Holen Sie sich die Stockscreener-App
132.09
0.38%
0.4935
Schlusskurs vom Vortag:
$131.60
Offen:
$130.93
24-Stunden-Volumen:
1.56M
Relative Volume:
1.38
Marktkapitalisierung:
$13.26B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$478.60M
KGV:
28.30
EPS:
4.6676
Netto-Cashflow:
$748.70M
1W Leistung:
+2.63%
1M Leistung:
+3.10%
6M Leistung:
-5.26%
1J Leistung:
+38.11%
1-Tages-Spanne:
$125.31
$134.01
1-Wochen-Bereich:
$125.31
$134.01
52-Wochen-Spanne:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
132.10 | 13.21B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.20 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.925 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.67 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
555.45 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today
Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance
Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - Yahoo Finance
Neurocrine Biosciences, Inc. entered into a definitive agreement to acquire Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others for $2.8 billion. - marketscreener.com
Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug - inc.com
Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal - MSN
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1 - Minichart
Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder - WSJ
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
UBS reiterates Neurocrine Bio stock rating on acquisition news - investing.com
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout - BioPharma Dive
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo Finance
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com
Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketNeurocrine Biosciences (NASDAQ:NBIX), Sol - Benzinga
Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - tipranks.com
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com
Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView
Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan
Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan
Neurocrine Biosciences to Acquire Soleno Therapeutics in $53-Per-Share Tender Offer and Merger - TradingView
Neurocrine Biosciences Inc if deal terminated under some circumstances Soleno will pay co termination fee of $95.3 million - marketscreener.com
Neurocrine Biosciences Inc If Deal Terminated Under Some Circumstances Soleno Will Pay Co Termination Fee Of $95.3 Million - TradingView
Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan
Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final) - marketscreener.com
This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barron's
Neurocrine to buy Soleno Therapeutics for $2.9B - Breakingthenews.net
Neurocrine to buy Soleno Therapeutics for $2.9 billion - Yahoo Finance
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine to acquire Soleno Therapeutics for $2.9 billion - Investing.com
Neurocrine wants to develop new obesity drugs. It’s spending $2.9 billion on a company to accelerate that move. - MarketWatch
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire
Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - CoinCentral
Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT (NBIX:NASDAQ) - Seeking Alpha
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment - ft.com
Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - Financial Times
Nisa Investment Advisors Reduces Neurocrine Biosciences Stake - National Today
Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Risks Report: Is Neurocrine Biosciences Inc a turnaround storyMarket Weekly Review & High Win Rate Trade Tips - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients - Sahm
Should You be Optimistic on Neurocrine Biosciences (NBIX)? - MSN
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NBIX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
8,437 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Nilsine Partners LLC - MarketBeat
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,133 |
0 |
39,230 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
3,352 |
0 |
7,969 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
1,600 |
0 |
6,313 |
| Gano Kyle | Chief Executive Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,807 |
0 |
147,610 |
| Gano Kyle | Chief Executive Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
4,907 |
0 |
146,661 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
5,407 |
0 |
21,066 |
| Onyia Jude | Chief Scientific Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
18,537 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,044 |
0 |
56,664 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,005 |
0 |
54,760 |
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
2,911 |
0 |
30,395 |
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):